LGALS3 and pulmonary fibrosis: TD139, an inhaled Gal-3 inhibitor, blocked the progression of lung fibrosis in a mouse bleomycin model, with a dose–response profile comparing favorably with that of the anti-fibrotic compound pirfenidone on total collagen deposition, and the inflammatory and fibrosis scores20.